[6-K] GSK plc Current Report (Foreign Issuer)

Rhea-AI Filing Summary

GSK plc reported routine share dealings by senior personnel involving American Depositary Shares (ADSs). On 2025-11-14, Non-Executive Director Dr Hal Barron acquired approximately 2,732.837 notional ADSs in his GSK Executive Supplemental Savings Plan account and 69 ADSs in his GSK 401(k) plan account, both through the reinvestment of dividends at a price of $47.1800 per ADS. On the same date, James Ford, SVP and Group General Counsel, acquired 50.851 notional ADSs in his Executive Supplemental Savings Plan account, also via dividend reinvestment at $47.1800 per ADS. All transactions took place on the New York Stock Exchange.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

​

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr Hal Barron
b)	Position/status	Non-Executive Director
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of notional ADSs within Dr Barron's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$47.1800	2,732.837
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2025-11-14
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr Hal Barron
b)	Position/status	Non-Executive Director
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADSs within Dr Barron's GSK 401(k) plan account following the reinvestment of dividends
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$47.1800	69
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2025-11-14
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of notional ADSs within Mr Ford's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$47.1800	50.851
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2025-11-14
f)	Place of the transaction	New York Stock Exchange (XNYS)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: November 18, 2025

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc

FAQ

What insider transactions did GSK (GSK) report in this Form 6-K?

GSK reported that senior personnel acquired American Depositary Shares (ADSs) and notional ADSs in company-related savings and 401(k) plans through the reinvestment of dividends at a price of $47.1800 per ADS on 2025-11-14.

How many GSK ADSs did Dr Hal Barron acquire through dividend reinvestment?

Dr Hal Barron acquired about 2,732.837 notional ADSs in his GSK Executive Supplemental Savings Plan account and 69 ADSs in his GSK 401(k) plan account, all at $47.1800 per ADS.

What was the nature of James Ford’s GSK ADS transaction?

James Ford, SVP and Group General Counsel, acquired 50.851 notional ADSs in his GSK Executive Supplemental Savings Plan account, following the reinvestment of dividends at $47.1800 per ADS.

On which exchange were the reported GSK ADS transactions conducted?

All of the reported ADS and notional ADS transactions for Dr Hal Barron and James Ford were conducted on the New York Stock Exchange (XNYS).

Are the reported GSK insider transactions part of a specific incentive or savings plan?

Yes. The acquisitions occurred within GSK-related plans: the GSK Executive Supplemental Savings Plan and, for Dr Hal Barron, also the GSK 401(k) plan, and resulted from dividend reinvestment.

What type of security was involved in these GSK insider transactions?

The transactions involved GSK American Depositary Shares (ADSs), identified by ISIN US37733W2044, including both actual ADSs and notional ADSs held in plan accounts.